Citi lowered the firm’s price target on Longboard Pharmaceuticals to $17 from $24 and keeps a Buy rating on the shares post the Q4 results. The analyst cites a higher pace of expenditures and dilution for the target drop.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on LBPH:
